Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

IQVIA Holdings Inc. (IQV) SEC Filings & Earnings Calls

EquiReason read 18 IQVIA Holdings Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-23 — IQVIA Inc. issued $2B of 6.375% senior notes due 2034 to refinance existing debt and repay revolver borrowings..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

IQVIQVIA Holdings Inc.Follow IQV — free
Diagnostics & Research · Healthcare
—
Price chart with a free account
Market cap
46.0B
P/E TTM
34.7
Dividend yield
—
52-week
—
Next earnings
27 Oct, in 3 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

23 Sep 20268-K · 1.01, 2.03IQVIA Inc. issued $2B of 6.375% senior notes due 2034 to refinance existing debt and repay revolver borrowings.open

Risks flagged

Higher interest expense from 6.375% coupon vs. 5.000% on redeemed notes increases annual interest cost.

“6.375% senior notes due 2034 issued to redeem 5.000% notes due 2026.”
Read the original on SEC EDGAR ↗
9 Sep 20268-K · 8.01IQVIA subsidiary intends to raise $2B via senior notes due 2034 at 6.375% to refinance existing debt and revolver; pricing and purchase agreement executed.open

Risks flagged

Increased leverage from new debt issuance, though used for refinancing.

“$2B new senior notes at 6.375% interest rate.”
Read the original on SEC EDGAR ↗
28 Jul 202610-QIQVIA reported Q2 2026 revenue of $4,368M (+8.7% YoY) with stable margins and increased restructuring costs.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$4.37B+9% y/y
Revenue · H1-2026$8.52B+9% y/y
Commercial Solutions Revenue · Commercial Solutions · Q2-2026$1.79B+9% y/y
R&D Solutions Revenue · Research & Development Solutions · Q2-2026$2.58B+9% y/y
Backlog · Research & Development Solutions · Q2-2026$34.20B
Operating Cash Flow · H1-2026$1.18B+16% y/y
Employees · Q2-202694,000

Risks flagged

Restructuring execution risk

“Restructuring costs increased to $63M in Q2 2026 from $32M in Q2 2025, with actions expected through 2027.”

High debt levels

“Total indebtedness of $16,081 million as of June 30, 2026.”

Interest expense increase

“Interest expense increased to $197M in Q2 2026 from $182M in Q2 2025 due to higher outstanding debt balances.”
Read the original on SEC EDGAR ↗
28 Jul 20268-K · 2.02Revenue $4.37B (+9% y/y); Adjusted EBITDA $994M (+9% y/y); Adjusted Diluted Earnings per Share $3.15 (+12% y/y); Guidance: Revenue guidance raised to $17,275M-$17,475M (mid-point 6.5% growth vs prior 5.8%); Adjusted EBITDA to $4,000M-$4,050earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$4.37B+9% y/y
Adjusted EBITDA · Q2-2026$994M+9% y/y
Adjusted Diluted Earnings per Share · Q2-2026$3.15+12% y/y
R&D Solutions Net New Bookings · Research & Development Solutions · Q2-2026$3.15B+19% y/y
R&D Solutions Contracted Backlog · Research & Development Solutions · Q2-2026$34.20B
Operating Cash Flow · Q2-2026$558M+26% y/y
Free Cash Flow · Q2-2026$360M+23% y/y

Guidance

Revenue guidance raised to $17,275M-$17,475M (mid-point 6.5% growth vs prior 5.8%); Adjusted EBITDA to $4,000M-$4,050M; Adjusted EPS to $12.80-$13.00

IQVIA raised full-year 2026 guidance across all key metrics, citing stronger organic revenue growth, record bookings, and favorable forward-looking indicators.

Risks flagged

Foreign exchange headwinds partially offset guidance raise; M&A integration risks remain.

“Guidance assumes ~20 bps FX tailwind vs prior 100 bps; M&A contribution assumed 200 bps vs prior 150 bps.”
Read the original on SEC EDGAR ↗
11 Jun 20268-K · 1.01, 2.03IQVIA Inc. issued €950M of 4.625% senior notes due 2033 to refinance existing indebtedness. Unsecured, semi-annual interest, callable with make-whole premium. Net proceeds used for debt refinancing and fees.open

Risks flagged

Refinancing risk managed; interest rate fixed at 4.625%.

“Notes bear interest at 4.625% per year, maturing 2033.”
Read the original on SEC EDGAR ↗
4 Jun 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen

Risks flagged

Interest rate risk locked at 4.625%.

“Notes bear interest at 4.625% per annum.”
Read the original on SEC EDGAR ↗
3 Jun 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen

Risks flagged

Potential refinancing risk if offering fails.

“Subject to market conditions.”
Read the original on SEC EDGAR ↗
7 May 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen

Risks flagged

Buyback may reduce financial flexibility.

“The Repurchase Program does not obligate the Company to repurchase any particular amount of common stock, and it may be modified, extended, suspended or discontinued at any time.”
Read the original on SEC EDGAR ↗
5 May 20268-K · 2.02Revenue $4.15B (+8% y/y); GAAP Net Income $274M; Adjusted EBITDA $932M (+6% y/y); Guidance: FY2026 Adj. Diluted EPS raised to $12.65-$12.95; revenue reaffirmed $17.15B-$17.35B; Adj. EBITDA reaffirmed $3.975B-$4.025Bearningsopen

Figures in the filing · each found in the filing text

Revenue · Q1-2026$4.15B+8% y/y
GAAP Net Income · Q1-2026$274M
Adjusted EBITDA · Q1-2026$932M+6% y/y
GAAP Diluted Earnings per Share · Q1-2026$1.61
Adjusted Diluted Earnings per Share · Q1-2026$2.90+7% y/y
Commercial Solutions Revenue · Commercial Solutions · Q1-2026$1.75B+12% y/y
R&D Solutions Revenue · R&D Solutions · Q1-2026$2.40B+6% y/y
R&D Solutions Contracted Backlog · R&D Solutions · Q1-2026$34.20B
R&D Solutions Net New Bookings · R&D Solutions · Q1-2026$2.50B
Operating Cash Flow · Q1-2026$618M+9% y/y

Guidance

FY2026 Adj. Diluted EPS raised to $12.65-$12.95; revenue reaffirmed $17.15B-$17.35B; Adj. EBITDA reaffirmed $3.975B-$4.025B

Raised Adj. EPS guidance on strong Q1 beat; reaffirmed revenue and EBITDA; strong backlog and bookings support outlook.

Risks flagged

High leverage

“Net debt $13.9B; net leverage ratio 3.62x trailing twelve-month Adjusted EBITDA.”

Foreign exchange exposure

“Guidance assumes ~100 bps FX tailwind; constant currency growth lower than reported.”
Read the original on SEC EDGAR ↗
5 May 202610-QRevenue $4.15B (+8% y/y); Net Income $514M (+4% y/y); Operating Cash Flow $618M (+9% y/y)open

Figures in the filing · each found in the filing text

Revenue · Q1-2026$4.15B+8% y/y
Net Income · Q1-2026$514M+4% y/y
Operating Cash Flow · Q1-2026$618M+9% y/y
Commercial Solutions Revenue · Commercial Solutions · Q1-2026$1.75B+12% y/y
R&D Solutions Revenue · Research & Development Solutions · Q1-2026$2.40B+6% y/y
R&D Solutions Backlog · Research & Development Solutions · Q1-2026$34.20B
Employees · Q1-202693,000

Risks flagged

Restructuring execution risk

“Restructuring costs incurred during 2026 and 2025 were due to ongoing efforts to streamline our global operations and reduce overcapacity to adapt to changing market conditions and integrate acquisitions.” · word for word

Foreign exchange exposure

“In the first three months of 2026, approximately 30% of our revenues were denominated in currencies other than the United States dollar.” · word for word

High leverage

“As of March 31, 2026, we had $15,908 million of total indebtedness.” · word for word
Read the original on SEC EDGAR ↗
23 Apr 20268-K · 5.02, 5.07Reported the departure of a director or principal officer (CEO/CFO change); submitted matters to a vote of security holdersopen

Risks flagged

Potential dilution from new equity plan.

“2026 Plan authorizes a range of performance- and time-based equity-based awards.”
Read the original on SEC EDGAR ↗
27 Feb 2026DEF 14AIQVIA filed its 2026 proxy statement (DEF 14A) detailing executive compensation, governance, and shareholder proposals.open

Figures in the filing · each found in the filing text

Revenue · FY2025$16.30B+6% y/y
Adjusted EBITDA · FY2025$3.80B+3% y/y
Adjusted Diluted EPS · FY2025$11.92+7% y/y
Free Cash Flow · FY2025$2.10B
Backlog · R&DS · FY2025$32.70B+5% y/y
Next Twelve Months Revenue from Backlog · R&DS · FY2025$8.30B+5% y/y
Net New Business (R&DS) · R&DS · FY2025$10.00B
Net New Customers (R&DS) · R&DS · FY2025400
Employees · FY202593,000
Voluntary Attrition Rate · FY202510.5%

Risks flagged

Industry headwinds and policy changes

“Through the first half of 2025, IQVIA’s stock was adversely impacted by policy changes affecting the industry with the stock price going from a high of $209.96 to its low at mid-year of $137.00.” · word for word

High leverage

“Ended 2025 with a Net Leverage Ratio of 3.63x” · word for word

Restructuring risk

“Completed a rigorous assessment of organizational structure and talent deployment to improve operational effectiveness, resulting in the elimination of approximately 3,300 roles” · word for word
Read the original on SEC EDGAR ↗
17 Feb 202610-KEmployees 93,000; Unique non-identified patient records 1,200,000,000; Proprietary data size 68open

Figures in the filing · each found in the filing text

Employees · 2025-12-3193,000
Unique non-identified patient records · Technology & Analytics Solutions · 2025-12-311,200,000,000
Proprietary data size · Technology & Analytics Solutions · 2025-12-3168
Data suppliers · Technology & Analytics Solutions · 2025-12-31150,000
Healthcare records received annually · Technology & Analytics Solutions · FY2025120,000,000,000
Clients · 2025-12-3110,000

Risks flagged

Contract termination risk

“Most of our Research & Development Solutions clients can terminate our contracts upon 30 to 90 days' notice.” · word for word

Data dependency risk

“Our Commercial Solutions information services are derived from data we collect from third parties. ... suppliers may increase restrictions on our use of such data, increase the price they charge us for data or refuse altogether to license the data to us.” · word for word

Cybersecurity risk

“Security breaches and unauthorized use of our IT systems and information, or the IT systems or information in the possession of our vendors, could expose us, our clients, our data suppliers or others to risk of loss.” · word for word
Read the original on SEC EDGAR ↗
5 Feb 20268-K · 2.02Revenue $4.36B (+10% y/y); Revenue $16.31B (+6% y/y); GAAP Net Income $514M (+18% y/y); Guidance: FY26 revenue guidance $17.15B-$17.35B vs FY25 $16.31B; Adjusted EBITDA $3.975B-$4.025B vs FY25 $3.788Bearningsopen

Figures in the filing · each found in the filing text

Revenue · Q4-2025$4.36B+10% y/y
Revenue · FY2025$16.31B+6% y/y
GAAP Net Income · Q4-2025$514M+18% y/y
GAAP Net Income · FY2025$1.36B-1% y/y
Adjusted EBITDA · Q4-2025$1.05B+5% y/y
Adjusted EBITDA · FY2025$3.79B+3% y/y
GAAP Diluted EPS · Q4-2025$2.99+24% y/y
Adjusted Diluted EPS · Q4-2025$3.42+10% y/y
R&D Solutions contracted backlog · R&D Solutions · Q4-2025$32.70B+5% y/y
R&D Solutions revenue · R&D Solutions · Q4-2025$2.33B+10% y/y

Guidance

FY26 revenue guidance $17.15B-$17.35B vs FY25 $16.31B; Adjusted EBITDA $3.975B-$4.025B vs FY25 $3.788B

Strong Q4 beat; FY26 guidance implies continued growth; backlog strength supports outlook.

Risks flagged

High leverage; net debt $13.7B; net leverage 3.63x. Interest expense expected to increase ~$80M in FY26.

“Net debt of $13,744 million; Net Leverage Ratio was 3.63x. Guidance includes step up in interest expense of approximately $80 million.”
Read the original on SEC EDGAR ↗
9 Dec 20258-K · 1.01, 2.03Entered a material definitive agreement (acquisition, partnership, or major contract); took on a material direct financial obligation, increasing leverageSEC ↗
5 Nov 20258-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)SEC ↗
28 Oct 20258-K · 2.02Revenue $4.10B (+5% y/y); GAAP Net Income $331M; Adjusted EBITDA $949M (+1% y/y); Guidance: FY2025 revenue $16,150M-$16,250M; Adjusted EBITDA $3,775M-$3,800M; Adjusted EPS $11.85-$11.95earningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2025$4.10B+5% y/y
GAAP Net Income · Q3-2025$331M
Adjusted EBITDA · Q3-2025$949M+1% y/y
GAAP Diluted EPS · Q3-2025$1.93
Adjusted Diluted EPS · Q3-2025$3.00
R&D Solutions quarterly bookings · R&D Solutions · Q3-2025$2.60B+13% y/y
R&D Solutions contracted backlog · R&D Solutions · Q3-2025$32.40B+4% y/y
Operating Cash Flow · Q3-2025$908M
Free Cash Flow · Q3-2025$772M+35% y/y
TAS revenue · Technology & Analytics Solutions · Q3-2025$1.63B+5% y/y

Guidance

FY2025 revenue $16,150M-$16,250M; Adjusted EBITDA $3,775M-$3,800M; Adjusted EPS $11.85-$11.95

Reaffirmed midpoint of FY2025 guidance and narrowed ranges; strong demand indicators including RFP growth of 20% YoY.

Risks flagged

Net leverage ratio 3.52x trailing twelve-month Adjusted EBITDA; debt $14,957M.

“Net Leverage Ratio was 3.52x trailing twelve-month Adjusted EBITDA; debt was $14,957 million.” · word for word

COVID-related revenue step-down of ~$100M in FY2025 guidance.

“Revenue guidance includes approximately $100 million of COVID-related revenue step-down, entirely in R&DS.” · word for word
Read the original on SEC EDGAR ↗
28 Oct 202510-QIQVIA reported Q3 2025 revenue growth of 5.2% YoY, with mixed margin performance and increased backlog.earningsopen

Figures in the filing · each found in the filing text

Total revenues · Q3-2025$4.10B+5% y/y
Backlog · Research & Development Solutions · Q3-2025$32.40B
Employees · Q3-202591,000
Technology & Analytics Solutions revenue · Technology & Analytics Solutions · Q3-2025$1.63B+5% y/y
Research & Development Solutions revenue · Research & Development Solutions · Q3-2025$2.26B+5% y/y
Contract Sales & Medical Solutions revenue · Contract Sales & Medical Solutions · Q3-2025$209M+16% y/y
Operating cash flow · 9M-2025$1.92B+5% y/y

Risks flagged

Cost inflation pressure

“Cost of revenues as a percentage of revenues increased from 64.6% to 66.5% in Q3 2025 vs Q3 2024, driven by compensation and related expenses.”

Restructuring execution risk

“Restructuring costs of $81 million for the first nine months of 2025, with actions expected to continue into 2026.”
Read the original on SEC EDGAR ↗

IQVIA Holdings Inc. — questions

What did IQVIA Holdings Inc. file recently?
18 SEC filings in the last 12 months. Latest: 8-K on 2026-09-23 — IQVIA Inc. issued $2B of 6.375% senior notes due 2034 to refinance existing debt and repay revolver borrowings.

Every figure on this page comes from IQVIA Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.